富马酸二甲酯在中重度斑块型银屑病中的临床应用:欧洲专家共识
富马酸二甲酯(DMF)已获欧洲药品管理局(EMA)批准用于需系统治疗的中重度慢性斑块型银屑病成人患者。本专家共识基于现有证据和真实世界临床经验,提供患者选择、剂量考量、监测及副作用管理的临床指导。
要点
- 富马酸酯类(FAEs)在欧洲S3指南中被推荐用于银屑病的诱导和长期治疗。
- Skilarence是首个获EMA批准用于银屑病的富马酸酯类药物,仅含富马酸二甲酯。
- 共识基于证据和真实世界经验,提供患者选择、剂量、监测及副作用管理指导。
核心结论
- 富马酸酯类在德国是使用最频繁的一线系统性银屑病治疗,累积治疗经验超过220000患者年。
- 富马酸酯类对中重度银屑病长期治疗显示出良好、持续的临床疗效和可接受的安全性。
- 欧洲S3指南推荐富马酸酯类用于银屑病的诱导和长期治疗。
研究设计与样本
- 制定机构与方法:欧洲专家会议,基于现有证据和集体真实世界临床经验形成共识。
主要发现
- 富马酸酯类最早于1959年用于银屑病研究,Fumaderm于1994年在德国获批用于严重银屑病,2008年标签扩展至中度银屑病。
- Fumaderm是富马酸酯类的组合,含富马酸二甲酯(主要活性成分)以及富马酸单乙酯(MEF)的钙、镁和锌盐。
- 2017年欧洲药品管理局批准Skilarence,一种新的口服富马酸二甲酯制剂,用于需系统治疗的中重度慢性斑块型银屑病成人患者。
关键数值与推荐
- 欧洲S3指南推荐富马酸酯类用于银屑病的诱导和长期治疗。
临床怎么用
- 共识提供基于证据和真实世界经验的指导,涵盖合适患者选择、富马酸二甲酯剂量考量、监测和副作用管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fumaric acid esters (FAEs) are a group of small molecules that were first investigated for the treatment of psoriasis in 1959. The first fumarate-based drug - Fumaderm® - was approved in Germany in 1994 for severe psoriasis and then in 2008, the label was expanded to include moderate psoriasis. Fumaderm is a combination of different FAEs: dimethyl fumarate (DMF), which is regarded as the main active component, plus calcium, magnesium and zinc salts of monoethyl fumarate (MEF). FAEs are the most frequently used first-line systemic psoriasis treatment in Germany, with an overall treatment experience comprising more than 220 000 patient-years. FAEs have demonstrated good, sustained clinical efficacy with an acceptable safety profile for the long-term treatment of patients with moderate-to-severe psoriasis. Indeed, the European S3-Guideline on the systemic treatment of Psoriasis vulgaris recommends FAEs for induction and long-term treatment. Until recently, FAEs were only licensed (for the psoriasis indication) in Germany, but were imported to many other European countries, such as The Netherlands, UK, Ireland, Austria and Italy, for the treatment of psoriasis. In 2017, the European Medicines Agency (EMA) approved Skilarence® , a new oral formulation of DMF, for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis in need of systemic therapy. Skilarence only contains DMF and is the first FAE for the treatment of psoriasis that has been approved by the EMA. This approval has given rise to a new oral treatment option for patients with moderate-to-severe plaque psoriasis across Europe. Here, we report the results of an expert meeting which was convened to deliver clinician-agreed consensus and real-world guidance on the clinical use of DMF in moderate-to-severe chronic plaque psoriasis. Guidance on appropriate patient selection, DMF dosage considerations, monitoring and side-effect management is offered based upon available evidence and collective real-world clinical experience.
引用
- Mrowietz U, Barker J, Boehncke WH, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. 2018. PMID: 30238510. doi:10.1111/jdv.15218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。